by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners
Crohn’s disease: Study on the efficacy and safety of risankizumab (FORTIFY) ClinicalTrials.gov ID: NCT03105102Sponsor: AbbVie Official title:A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension...
by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners
Crohn’s disease: Study on subcutaneous guselkumab (GRAVITI) ClinicalTrials.gov ID: NCT05197049Sponsor: Janssen Research & Development, LLC Official title:Randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy...
by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners
Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD) ClinicalTrials.gov ID: NCT05242471Sponsor: Janssen Research & Development, LLC Official title:Randomized, double-blind, active- and placebo-controlled,...
by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners
Ulcerative colitis: Combination study with guselkumab and golimumab (DUET-UC) ClinicalTrials.gov ID: NCT05242484Sponsor: Janssen Research & Development, LLC Official title:A Phase 2b Randomized, Double-Blind, Active and Placebo-Controlled, Multicenter,...
by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners
Ulcerative colitis: Study on the efficacy and safety of risankizumab ClinicalTrials.gov ID: NCT03398135Sponsor: AbbVie Information provided by: AbbVie (responsible party) Official title:Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance...
